News And Announcements
Next investors take positives as profits fall and will fall again
Profits fell at Next for the third year in a row in 2017 and are expected to fall again in 2018 as falling store sales and good online growth largely cancel each other out and the clothing retailer looks to "attack costs" and "defend sales and profitability".
Melrose says 'disregard' Mergermarket story, to waive CFIUS clearance condition
In its second instalment of the day, turnaround specialist Melrose Industries said a story published by Mergermarket on Thursday suggesting that it was confident of meeting the 50. 1% minimum threshold for shareholder acceptances should be disregarded.
Henry Boot FY profit up, hails good start to 2018
Construction and property development business Henry Boot posted a rise in full-year profit on Friday as revenue increased and it hailed a good start to 2018.
SDX Energy posts stellar set of full-year figures
SDX Energy issued its year-end financial results for the 12 months to 31 December on Friday, withy revenue surging to $39. 2m from £12. 9m in 2016.
PipeHawk revenue falls during 'most peculiar' six months
PipeHawk posted its unaudited results for the six months ended 31 December on Friday, with revenue falling to £2. 31m from £3m in the same period last year.
Flowtech Fluidpower chairman wins AIM non-executive accolade
Flowtech Fluidpower announced on Friday that its non-executive director and chairman Malcolm Diamond has been recognised at the 2018 Non-Executive Director Awards, winning the award in the FTSE AIM category.
Grafenia upbeat on strategy despite ongoing headwinds
Graphic arts systems company Grafenia updated the market on its trading on Friday, reporting that since its last update, trading had been mixed.
ImmuPharma anticipating latest Lupuzor test results in April
Specialist drug discovery and development company ImmuPharma announced on Friday that it has been informed by Simbec-Orion, the contract research organisation conducting its ‘Lupuzor’ pivotal Phase III trial study, that 'database lock' was expected on 6 April, with top line results announced by mid-April.
Joint venture discussions still ongoing at i3 Energy
Independent oil and gas company i3 Energy updated the market on its funding progress on Friday, following its announcement on 31 January that joint venture discussions were at an “advanced stage” with multiple industrial partners.
Cenkos posts jump in profit but cautious on outlook
Stockbroker Cenkos Securities posted a surge in full-year profit on Friday but sounded a cautious note on its outlook.
Fevertree founder Charles Rolls sells twice as many shares as expected
Posh mixers maker Fevertree Drinks slumped on Friday as co-founder and deputy chairman Charles Rolls sold 3m shares in the company, or a 2. 6% stake.
Indivior warns of potential sales collapse after US court ruling
Indivior warned of a potential "rapid and material loss" of sales from its main revenue-generating product after a US court found a rival generic challenger of the drug did not infringe on its patents.
Big Yellow buys new site in Hove
Self-storage company Big Yellow has acquired a site in Hove, west of Brighton, for a new 56,000 square feet store.
Smiths Group profit drops, says FX headwinds to persist
Smiths Group tumbled on Friday after it posted a 12% drop in interim profit as revenue fell and while the engineering company did reiterate its guidance for the year, it also warned that forex headwinds would persist.
Joe Hudson to take up Ibstock reins on 4 April
Ibstock updated the market on its CEO succession plan on Friday, confirming that Joe Hudson would be appointed as chief executive with effect from 4 April, on completion of the handover period with retiring CEO Wayne Sheppard.
John Laing Infrastructure Fund boasts year of solid progress
John Laing Infrastructure Fund issued its results for the year ended 31 December on Friday, declaring a dividend of 3. 57p per share for the last six months of the year, up 2. 5%.
Aviva scraps plans to cancel preference shares
Aviva has decided not to cancel £450m worth of preference shares following "strong feedback and criticism" from a large number of investors.
GSK gets approval for Shingrix in Europe and Japan
GlaxoSmithKline announced on Friday that the European Commission has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN) in adults aged 50 years or older.
GlaxoSmithKline confirms it's no longer interested in Pfizer
GlaxoSmithKline confirmed on Friday that it has withdrawn from the process relating to Pfizer's Consumer Healthcare business.